HIV Policy and Advocacy

Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.

Thirty years ago, the NIH legend deftly negotiated between bureaucrats and activists. As part of Trump’s COVID-19 team, can he negotiate between loyalty and truth?

Activist and member of the state task force Annette Gaudino would like the public to know.

Many HIV service organizations say they’re open to hiring TGNC employees, but advocates say most have a long way to go.

The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.

Advocate D. Rashaan Gilmore explains how white-led HIV organizations in the U.S. engage in movement capture—e.g., the co-opting of Black racial justice efforts—under the guise of ending the HIV epidemic.

Jan. 2, 2020: Cancer treatment among people with HIV in the Obamacare era; chemotherapy, CD4 count, and mortality; cutting meds to cut costs; tailoring interventions on the microepidemic level.

One New York-based provider who works specifically with trans and gender non-conforming patients outlines what needs to change in the health care world to get Black trans women the care they deserve.

Even after a series of reforms in 2015, advocates say U.S. policy still discriminates and furthers HIV stigma. Anthony Santella, Dr.P.H., M.P.H., has a better idea.

Re-entry planning can help prevent opioid overdose and enable people living with HIV to connect with and stay in care.